We examined expression of B cell-activating factor of the TNF family ( 
Introduction
B-cell chronic lymphocytic leukemia (CLL) is characterized by the accumulation of monoclonal B-cells in the blood, secondary lymphoid tissues, and marrow. 1 The leukemia cells primarily are arrested in the G 0 /G 1 -phase of the cell cycle and appear resistant to programmed cell death. 2, 3 Despite their apparent longevity in vivo, CLL cells typically undergo spontaneous apoptosis under conditions that support the growth of human B cell lines in vitro. [4] [5] [6] [7] This implies that the factors essential for survival are not intrinsic to the CLL B cell. [4] [5] [6] 8 In vitro a subset of blood mononuclear cells from patients with CLL can differentiate into large, round, adherent cells that can attract leukemia cells and protect them from undergoing apoptosis. 9 When removed from these cells, the CLL B cells high , CD83 negative , CD106 negative ) that is distinct from those of monocytes, macrophages, or blood-derived dendritic cells. 10 Abundant cells with the morphology and phenotype of NLC are present in secondary lymphoid tissues of patients with CLL, 10 suggesting they might also function to promote leukemia cell survival in vivo.
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The mechanisms whereby NLC promote CLL cell survival are not resolved.
NLC express high-levels of stromal-derived factor-1 alpha (SDF-1α), 9 a CXC chemokine capable of inducing chemotaxis, phosphorylation of mitogen activated protein kinases (MAPK), and improved survival of CLL cells in vitro. 9 Nevertheless, the viability of CLL B cells cultured with even high concentrations of SDF-1α is not as high as that achieved by co-culture with NLC, indicating that factors other than SDF-1α also might be responsible for promoting CLL B cells survival by NLC in vitro.
Investigators have reported that CLL cells express B-lymphocyte stimulator (BLyS), otherwise known as B cell-activating factor of the tumor necrosis factor family. [11] [12] [13] BAFF is a type II transmembrane protein that can act in a membrane-bound or soluble form to promote B cell survival (reviewed by Mackay and colleagues 14 ).
Moreover, in mice, disruptive mutations of either BAFF or its receptor, BAFF-R, causes profound loss of mature B cells, indicating that BAFF-BAFF-R interactions are critical for the differentiation and/or survival of mature B cells. [15] [16] [17] CLL B cells also were found to express the primary BAFF receptor (BAFF-R), as well as two other receptors that can interact with BAFF, namely B-cell maturation antigen (BCMA) and transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI). 13 Kern and colleagues also detected expression of BAFF on the surface of CLL cells, implying that BAFF may function in an autocrine manner to support CLL B cell survival.
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Two of the BAFF receptors, namely BCMA and TACI, also can bind a proliferation inducing ligand (APRIL), a factor that also can contribute to B cell survival. 14 The third receptor for BAFF, namely BAFF-R, is specific for BAFF and cannot bind to APRIL. APRIL originally was found in tumor cells and supposedly is 
Materials And Methods

Cell Preparation
After obtaining informed consent, blood samples were collected from patients at the University of California, San Diego (UCSD) Medical Center who satisfied diagnostic and immunophenotypic criteria for common B-cell CLL. 1 University, Japan).
Cell Isolation
Isolated blood mononuclear cells of patients with CLL were incubated with saturating amounts of "Dynabeads" coated with anti-CD2 or anti-CD14 mAbs (Dynal A.S, Oslo, Norway). Bead-bound cells were removed with a strong magnetic field.
Following depletion, less than 0.5% of cells were CD2 + or CD14 + , respectively, whereas more than 99% were CD19 + , as assessed via flow cytometry (data not shown).
Peripheral normal CD19 + B cells were purified from the buffy-coat of blood samples collected from adult volunteers at the San Diego Blood Bank using CD19-Dynabeads 
Immunoblot Analysis
Cell lysates were prepared with RIPA buffer (10 mM Tris (pH 7.4), 150 mM NaCl, 1% Triton x 100, 1% deoxycholate, 0.1% SDS, 5 mM EDTA), containing 1 mM PMSF, 0.28 TIU/ml aprotinin, 50 µg/ml leupeptin, 1 mM benzamidine, 0.7 µg/ml pepstatin.
Lysates were normalized for total protein (20 µg), subjected to SDS-PAGE (4-15% gradient gels, Bio-Rad, Hercules, CA) and immunoblot assay. We incubated the blots with secondary antibodies that were conjugated with horseradish peroxidase. Blots then were prepared for enhanced chemiluminescence (ECL) detection system 
Subcellular Fractionation and Detection of Cytoplasmic or Nuclear NF-κB
For fractionation experiments, cells were collected by centrifugation and washed with PBS. The cell pellet containing 5 x 10 6 cells was suspended in 100 µl of hypotonic buffer (50 mM Tris (pH7.4), 5 mM EDTA, 10 mM NaCl, 0.05% NP-40, 1 mM PMSF, 10 µg/ml Aprotinin, 10 µg/ml Leupeptin, 10 µg/ml Pepstatin, 10 mM β-Glycerophosphate, 1
mM Na-Vanadate, 1 mM NaF). After 10 minutes the lysate was spun and the supernatant was collected as cytoplasmic lysates. The pellet was washed 5 times in hypotonic buffer containing 0.1% NP-40. The remaining pellet was suspended in 100 µl RIPA buffer containing protease and phosphatase inhibitors. After an appropriate amount of 3x sample buffer (200 mM Tris (pH 6.8), 30 mM EDTA, 30% Glycerol, 6% SDS) was added, the sample was boiled for 10 minutes, spun for 10 minutes and the supernatant was recovered as nucleus lysates. Anti-NF kappa B p52 and p65 were purchased from Upstate Biotechnology. Anti-SP-1 was purchased from Santa Cruz Biotechnology (Santa Cruz, CA).
Measurement Of Cell Viability
Freshly thawed CLL B cells were cultured at the concentration of 1 x10 6 /ml under various conditions. Determination of CLL cell viability in this study was based on the analysis of mitochondrial transmembrane potential (∆Ψ m ) using 3,3'-dehexyloxacarbocyamine iodine (DiOC 6 ) and cell membrane permeability to PI, as described. 22 For viability assays, 100 µl of the cell culture was collected at the indicated time points and transferred to polypropylene tubes containing 100 µl of 60 nmol/l DiOC 6 (Molecular Probes) and 10 µg/ml PI in FACS buffer. The cells then were incubated at DiOC 6 and at 600 nm (FL-3) for PI.
Statistical Analysis
Results are shown as mean ± S.D. of at least 3 samples each. For statistical comparison between groups, the Student t test or the Bonferroni t test was used.
Analyses were performed using Glanzman's "Primer of Biostatistics" software (McGrawHill Inc., New York, NY).
Results
Expression of BAFF mRNA and Protein on CLL Cells and NLC
We (Figure 1D ), or immunofluorescence microscopy ( Figure 1E ). These data indicate that NLC express large amounts of BAFF protein relative to that expressed by CLL B cells.
Expression of APRIL mRNA and Protein on CLL Cells and NLC
We also examined the PBMC of patients with CLL for expression of APRIL mRNA with the same techniques used for evaluating the expression of BAFF. In contrast to our studies on BAFF mRNA, we found that rigorous depletion of CD14 + cells from the PBMC did not lower the amount of APRIL mRNA detected in each sample tested (440 ± 308 Units in PBMC and 348 ± 228 Units in isolated CLL B cells, n = 11, In contrast, the amounts of APRIL mRNA detected in differentiated NLC was significantly higher ( Figure 2B ; 1595 ± 1090, n=11) than that of non-differentiated CD14 + blood mononuclear cells. Moreover, NLC had significantly greater amount of APRIL mRNA than that noted in the isolated leukemia B cells or isolated CD19 + blood B cells of normal donors (P < 0.01, Bonferroni t test, Figure 2B ).
We evaluated for expression of APRIL by immunoblot analysis. As seen in Figure 2C , total lysates from NLC had higher amounts of APRIL than did CD14 + blood mononuclear cells, purified CLL B cells, or isolated CD19 + blood B cells of normal donors. NLC also were found to express high levels of APRIL relative to CLL B cells by immunofluorescence staining ( Figure 2D ).
For Figure 3A ). In contrast, there was no decline in leukemia-cell viability in such co-cultures when we added saturating amounts of BAFF-R:Fc ( Figure 3A) , which in parallel studies were found capable of inhibiting B cell 
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Because NLC express BAFF, APRIL, and SDF-1α, we examined whether these factors together could support CLL B cell survival better than either factor alone. The viability of isolated CLL B cells was highest when co-cultured with NLC ( Figure 5 ).
However, isolated CLL B cells co-cultured with rhBAFF plus SDF-1α, or rhAPRIL plus SDF-1α, had a significantly greater viability than that of CLL B cells cultured with any one factor alone (Figure 4) . Collectively, these data support the notion that BAFF or APRIL promotes leukemia cell survival via a mechanism(s) independent of that used by SDF-1α.
Effects of rhBAFF, rhAPRIL, or SDF-1α on Signaling Pathways in CLL B Cells
We examined the intracellular signaling pathways stimulated by rhBAFF, rhAPRIL, or SDF-1α at concentrations that can promote CLL B cell survival in vitro. 
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Prior studies indicated that BAFF could induce activation of the NF-κB2 in normal B cells, 17, 23 a pathway that appears critical for the growth and/or survival of normal B cells. 24 Such activation involves processing of p100 to p52 with subsequent translocation of p52 to the nucleus. We found that rhBAFF could induce activation of NF-κB2 also in CLL B cells ( Figure 5A ). In contrast, we did not observe activation of NF-κB2 in CLL cells treated with rhAPRIL or SDF-1α, even at concentrations that could support CLL cell survival in vitro. Both rhBAFF and rhAPRIL, however, induced degradation of the inhibitor of kappa B (IκBα) and translocation of p65 to the nuclear fraction, indicating activation of the classical NF-κB pathway ( Figure 5B ). SDF-1α, on the other hand, did not have this activity ( Figure 5 ).
We also examined for phosphorylation and activation of AKT, which prior studies found also could enhance CLL B cell survival. 25, 26 In contrast to SDF-1α, 9 we found 10 .
We investigated whether BAFF and/or APRIL on NLC could contribute to their capacity to promote leukemia cell survival in vitro. Previous studies showed BCMA-Fc could impair leukemia-cell viability over time when this decoy receptor was added to isolated leukemia cells.
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However, we did not observe this effect on the viability of of NLC on CLL cell survival. Although the studies in knock-out mice showed that APRIL appeared to be dispensable for developing normal immune systems, 34 a recent study by Planelles found that APRIL may play a role in the pathogenesis of B1-cell malignancies, namely CLL. 35 In this light, strategies that only interfere with BAFF/BAFF-R interactions may not be sufficient to affect CLL cell viability in vivo Previously, we reported that NLC also express SDF-1α, a chemokine that can trigger phosphorylation of p44/42 MAPK ERK1/2 and enhance CLL cell survival in vitro. 9 Although some studies have suggested that the ERK pathway might not be involved in preventing spontaneous apoptosis of CLL B cells, 36 suppression of ERK activity is seen in CLL B cells undergoing drug induced apoptosis, 37, 38 suggesting that this pathway is important for survival of CLL B cells.
For personal use only. on August 31, 2017. by guest www.bloodjournal.org From Since SDF-1α had an additive effect on the viability of isolated CLL cells cultured with BAFF and/or APRIL (Figure 4) , we reasoned that BAFF or APRIL might promote CLL cell survival via a pathway(s) that is distinct from that of SDF-1α. Consistent with this notion, we found that SDF-1α, in addition to its noted capacity to induce phosphorylation of ERK1/2 MAPK, could induce CLL B cells activation of phosphatidylinositol 3-kinase (PI3K) AKT (Figure 6 ), a pathway that is essential for the survival of CLL B cells. 25, 26 These findings are consistent with those of others who found that SDF-1α could induce activation of AKT in other types of cells besides leukemia B cells. [39] [40] [41] [42] Recently, Moreaux and colleagues reported that addition of exogenous BAFF to myeloma cells induced late activation of both ERK1/2 and AKT, 42 but the direct influence of BAFF on these two pathways was not resolved. In the study presented here, it appears that neither pathway is activated in CLL cells by rhBAFF or rhAPRIL, indicating that these factors must use other mechanisms to protect CLL B cells from spontaneous apoptosis.
Some TNF super family proteins like BAFF trigger their functions by activating NF-κB. Two main pathways -the canonical and alternative pathway -regulate the activity of NF-κB. 24 Activation of the canonical pathway results from degradation of the inhibitor of NF-κBα (IκBα), which is induced upon its phosphorylation by the beta subunit of the IκB kinase (IKK) complex, IKKβ. 43 This leads to nuclear translocation of active NF-κB heterodimers (that are composed of p65, c-Rel or p50) where they can effect changes in gene expression. As noted for lymphoma or CLL B cells, 11, 12 concentrations of rhBAFF or rhAPRIL required for optimal enhancement of CLL cell survival also induced degradation of IκBα and translocation of p65 to the nucleus,
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indicating that either factor can activate the canonical NF-κB pathway. Activation of the canonical NF-κB pathway in normal B cells appears secondary to the capacity of BAFF or APRIL to interact with BCMA, or BCMA and/or TACI, respectively. 44 Alternative pathway activation results from processing of NF-κB2 p100 to p52, which is triggered by the phosphorylation of NF-κB2 p100 by the alpha subunit of the IKK complex, namely IKKα. 43 This allows for nuclear translocation of p52 along with RelB, where this complex can influence expression of genes that are distinct from those regulated by the canonical NF-κB pathway. We noted that rhBAFF, but not rhAPRIL or SDF-1α, could induce degradation of p100 to p52 and translocation of p52 to the nucleus. Because the BAFF-R interacts with BAFF, but not APRIL, the selective activation of p100 processing by BAFF suggests that the BAFF-R may be distinct from BCMA or TACI in its capacity to activate the alternative NF-κB pathway in CLL B cells. This is similar to the interaction of BAFF with its receptor on normal B cells, which also promotes processing of NF-κB2. 17, 45 Moreover, studies have shown that IKKα is required for B cell maturation and formation of secondary lymphoid organs. 46, 47 However, because treatment of co-cultures of CLL cells and NLC with BAFF-R:Fc failed to inhibit the protective effect of NLC on leukemia cell survival, it appears that activation of the canonical pathway may obviate the requirement for activation of the alternative NF-κB pathway in CLL to promote leukemia cell survival, at least in the in vitro culture conditions used in this study.
Finally, we evaluated for expression of Bcl-2-family-member proteins that can influence the resistance or sensitivity of CLL cells to apoptosis. Prior studies found that BAFF can up-regulate expression of Bcl-2 in most B cells.
14,12 BAFF induced up-
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regulation of Bcl-2 was less apparent in CLL B cells, possibly secondary to the constitutive high-level expression of this anti-apoptotic protein in this leukemia. 48 However, we found that rhBAFF, rhAPRIL, or NLC could induce CLL B cells to express high-levels of Mcl-1 ( Figure 7 , and data not shown). Like Bcl-2, Mcl-1 also appears to play a role in the resistance of CLL B cells to drug induced apoptosis, 49, 50 and patients with CLL who fail to achieve complete remission after chemotherapy tend to have high levels of Mcl-1.
3,51
There are several reports that AKT or ERK1/2 regulate the expression of Mcl-1 in various types of cells.
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On the other hand, O'Connor reported that the persistence of plasma cells in mice was associated with a BAFFmediated up-regulation of Mcl-1.
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In the present study, we found that rhBAFF or 
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when CLL B cells were cultured with NLC, suggesting that yet additional NLC factors are involved in promoting leukemia-cell survival. In this regard, it is noteworthy that Deaglio and colleagues recently found that NLC also express high-levels of CD31 and plexin-B1, which also can contribute in part to the capacity of NLC to sustain CLL cell viability. 59 Conceivably, strategies that can target one or more of the mechanisms whereby NLC sustain CLL cell survival could have therapeutic potential for patients with this disease. CLL B cells were cultured with or without NLC, or with SDF-1α (500 ng/ml) or rhBAFF 
